GERNHIGH SIGNALFINANCIAL10-K

GERN experienced a substantial revenue decline while meaningfully reducing operating losses, suggesting a major shift in business operations during the transition to commercial operations.

The dramatic revenue drop combined with significantly improved operating performance indicates GERN may be in a transitional phase of its commercialization strategy for RYTELO. The substantial improvement in cash burn and operating losses suggests better expense management, though the revenue decline raises questions about commercial execution in the near term.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

GERN's financial profile shifted dramatically with revenue declining substantially while operating losses improved meaningfully from -$173.7M to -$68.6M. Operating cash flow also improved notably to -$111.0M, indicating better expense control and cash management. The balance sheet shows modest deterioration with current liabilities increasing 26.3% and stockholders' equity declining 19.4%, but the overall picture suggests a company working through commercial launch challenges while achieving better operational efficiency.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-82.7%
$6.2M$1.1M

Revenue declined 82.7% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
+60.5%
-$173.7M-$68.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+52.2%
-$174.6M-$83.5M

Net income grew 52.2% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+49.2%
-$218.6M-$111.0M

Operating cash flow surged 49.2% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
+26.3%
$88.3M$111.5M

Current liabilities rose 26.3% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
-19.4%
$280.3M$225.9M

Equity decreased 19.4% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
As of February 20, 2026 , there were 640,544,661 s hares of common stock outstanding.
The risks and uncertainties referred to above include, without limitation, risks and uncertainties related to: (a) whether we are successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with lower-risk myelodysplastic syndromes, or lower-risk MDS, with transfusion dependent anemia; (b) whether the U.S.
Although we have established commercial operations and sales, marketing and distribution infrastructure for RYTELO, we have limited experience in sustaining and scaling these operations and our commercialization efforts may be unsuccessful or less successful than anticipated.
We face competition from existing products, product candidates and technologies, and competitors may develop new products and technologies.
If these products, product candidates or technologies are deemed by the healthcare community to be superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.
+7 more — sign up free →
REMOVED
As of February 21, 2025 , there were 636,904,470 sh ares of common stock outstanding.
1 Forward Looking Statements This Report, including Business in Part I, Item 1 of this Report and Management s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of this Report, contains forward looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Geron Corporation, or Geron or the Company, to differ materially from those expressed or implied by such forward looking statements.
We have limited experience as a commercial company and our sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated.
If we do not obtain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.
To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →